Nayan Patel, MD
Internal Medicine · Santa Barbara, CANPI 1134578024
Payments from drug & device makers
Across 298 payments — averaging $72.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$11K
- GSK$1K
- United Therapeutics Corporation$1K
- AstraZeneca$954
- Actelion Pharmaceuticals US, Inc.$750
- Boehringer Ingelheim$682
- plus $6K from 30 others
What the payments were for
- Consulting fees$2001%
- Speaking & faculty fees$5002%
- Travel & lodging$1,0985%
- Food & beverage$10,47649%
- Education$9,26243%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 15 | $10,724 |
| GSK | 57 | $1,323 |
| United Therapeutics Corporation | 27 | $1,149 |
| AstraZeneca | 27 | $954 |
| Actelion Pharmaceuticals US, Inc. | 14 | $750 |
| Boehringer Ingelheim | 21 | $682 |
| Pulmonx Corporation | 12 | $574 |
| Inari Medical, Inc. | 4 | $562 |
| Regeneron Healthcare Solutions, Inc. | 12 | $510 |
| Jazz Pharmaceuticals Inc. | 4 | $489 |
| La Jolla Pharmaceutical Company | 8 | $426 |
| Bayer | 7 | $331 |
| Insmed, Inc. | 14 | $316 |
| Grifols USA, LLC | 7 | $289 |
| Sanofi | 7 | $283 |
| Paratek Pharmaceuticals, Inc. | 6 | $217 |
| Harmony Biosciences LLC | 2 | $215 |
| Vapotherm Inc | 2 | $206 |
| Sanofi-aventis U.S. LLC | 2 | $173 |
| Haemonetics Corporation | 3 | $155 |
| Novartis | 6 | $143 |
| Baxter Healthcare | 5 | $141 |
| Johnson & Johnson | 1 | $125 |
| Electromed, Inc. | 6 | $121 |
| AbbVie | 5 | $113 |
| Shionogi Inc | 4 | $105 |
| Merck | 4 | $78 |
| Amgen | 3 | $67 |
| Viatris Specialty LLC | 2 | $63 |
| Verona Pharma, Inc. | 2 | $58 |
| Mylan Specialty L.p. | 3 | $53 |
| Pfizer | 2 | $40 |
| Pinnacle Biologics, Inc | 1 | $31 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $30 |
| Philips North America LLC | 1 | $19 |
| Ambu Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$7,542
- ION$3,000
- FLOWTRIEVER CATHETER, S$487
- CT THROMBECTOMY SYSTEM KIT$487
- UPTRAVI$393
- OPSUMIT$393
- OFEV$366
- XYWAV$364
- NUCALA$344
- CHARTIS CATHETER$282
- ZEPHYR DELIVERY CATHETER$282
- ZEPHYR ENDOBRONCHIAL VALVE$282
- PULMONX CHARTIS TABLET CONSOLE$282
- Adempas$200
- Prolastin-C Liquid$145
- GIAPREZA$143
- BREZTRI$126
- SUNOSI$125
- FASENRA$125
- XARELTO$125
How this compares
$21,536 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 18 | $192,862 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 76 | $53,676 |
| EliquisApixaban | 23 | $20,128 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $18,759 |
| Incruse ElliptaUmeclidinium Bromide | 49 | $16,973 |
| Advair HfaFluticasone Propion/Salmeterol | 37 | $13,712 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 25 | $10,282 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $9,169 |
| Spiriva HandihalerTiotropium Bromide | 14 | $7,044 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,659 |
| BreynaBudesonide/Formoterol Fumarate | 23 | $5,174 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $4,345 |
| Wixela InhubFluticasone Propion/Salmeterol | 37 | $3,463 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $2,865 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 94 | $2,604 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat | $682 | $198,52029 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta, Anoro Ellipta | $1,323 | $99,691190 claims |
| PfizerEliquis | $40 | $20,12823 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $954 | $13,51428 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Santa Barbara
- Kristin CastorinoSanta Barbara$10.9M
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.